LivaNova PLC (LIVN)vsStryker Corporation (SYK)
LIVN
LivaNova PLC
$63.30
+1.44%
HEALTHCARE · Cap: $3.40B
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 1709% more annual revenue ($25.12B vs $1.39B). SYK leads profitability with a 12.9% profit margin vs -17.5%. LIVN appears more attractively valued with a PEG of 0.73. SYK earns a higher WallStSmart Score of 65/100 (C+).
LIVN
Hold48
out of 100
Grade: D+
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LIVN.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -19.2% — below average capital efficiency
Earnings declined 45.6%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LIVN
The strongest argument for LIVN centers on PEG Ratio, Price/Book. Revenue growth of 12.1% demonstrates continued momentum. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : LIVN
The primary concerns for LIVN are Piotroski F-Score, Return on Equity, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LIVN profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.95 — expect wider price swings.
LIVN is growing revenue faster at 12.1% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 48/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?